YOU WONT BELIEVE: Dupixent | Mind Blowing Facts

What to Expect From Regeneron Pharmaceuticals' Next Quarterly Earnings Report

Regeneron Pharmaceuticals will release its third-quarter earnings later this month, and analysts anticipate a double-digit bottom-line growth.

Barchart · Oct 15

3 Beaten-Down Blue-Chip Stocks to Buy Now on the Dip

With hundreds of stocks hitting new 52-week lows, contrarian stock pickers may find opportunity in PepsiCo, Sanofi and Weyerhaeuser. All three trade at deep discounts, offer high dividend yields and have catalysts for long-term recovery.

Barchart · Sep 30

Sanofi Hit With Shock As Flagship Drug Successor Disappoints Investors

French drugmaker Sanofi SA (NASDAQ:SNY) stock fell sharply Thursday after late-stage trial results for amlitelimab, its potential successor to blockbuster eczema drug Dupixent, failed to match investor expectations, raising fresh doubts about the company’s ability to sustain its dermatology franchise once patent protections expire.

Benzinga · Sep 4, 2025

FDA Approves Regeneron and Sanofi's Dupixent (dupilumab) For Eosinophilic Esophagitis (EoE) Ahead of Schedule

The U.S. Food and Drug Administration (FDA) has approved Regeneron Pharmaceuticals, Inc.

Benzinga · May 20, 2022

5 Non-Cyclical Stocks to Buy Now if You're Worried About a Recession

As surging inflation and energy prices foster recessionary fears, it could be wise to bet on non-cyclical stocks because they tend to outperform the broader market when economic growth slows. Given the inelastic demand for their companies’ products, we think the shares of United Parcel Service (UPS), British American Tobacco…

StockNews.com · Apr 18, 2022

Second Dupixent Phase 3 Trial Confirms Significant Improvements In Inflammatory Skin Disease

Sanofi SA (NASDAQ: SNY) and Regeneron Pharmaceuticals Inc (NASDAQ: REGN) have 

Benzinga · Jan 19, 2022